- Report
- October 2024
- 188 Pages
Global
From €3181EUR$3,545USD£2,738GBP
€3534EUR$3,939USD£3,042GBP
- Report
- April 2025
- 175 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- May 2024
- 137 Pages
Global
From €5831EUR$6,499USD£5,019GBP
- Report
- February 2025
- 184 Pages
Global
From €4038EUR$4,500USD£3,475GBP
- Report
- April 2024
- 115 Pages
Global
From €4038EUR$4,500USD£3,475GBP
- Report
- August 2022
- 110 Pages
Global
From €4262EUR$4,750USD£3,668GBP
- Report
- July 2023
- 223 Pages
Global
From €4038EUR$4,500USD£3,475GBP
- Report
- June 2023
- 22 Pages
Global
€10992EUR$12,250USD£9,460GBP
- Report
- April 2025
- 50 Pages
Global
From €2378EUR$2,650USD£2,047GBP
- Book
- July 2023
- 1568 Pages
Methimazole is a drug used to treat endocrine and metabolic disorders, such as hyperthyroidism. It works by blocking the production of thyroid hormones, which helps to reduce the symptoms of the disorder. It is available in both oral and topical forms, and is usually taken once or twice a day. Side effects of the drug include rash, nausea, and headache.
Methimazole is a widely used drug in the endocrine and metabolic disorder market. It is used to treat a variety of conditions, including Graves' disease, toxic nodular goiter, and thyroid cancer. It is also used to treat hyperthyroidism in pregnant women.
The market for Methimazole is highly competitive, with many companies offering the drug. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and GlaxoSmithKline. Show Less Read more